Table 4.
Univariate analyses of metastasis‐free survival, locoregional control, and overall survival
| MFS | LRC | OS | ||||
|---|---|---|---|---|---|---|
| Covariate | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value |
| T‐Stage (T4/3 vs. T2/1) | 2.488 (1.745–3.547) | <0.001 | 1.646 (1.260–2.152) | <0.001 | 2.691 (2.133–3.393) | <0.001 |
| N‐Stage (N3/2 vs. N1/0) | 3.617 (2.480–5.274) | <0.001 | 2.107 (1.605–2.764) | <0.001 | 2.388 (1.904–2.995) | <0.001 |
| Lesion | <0.001 | <0.001 | <0.001 | |||
| Oral cavity vs. NPC) | 2.965 (1.511–5.816) | 0.002 | 5.500 (3.396–8.907) | <0.001 | 8.215 (5.526–12.213) | <0.001 |
| Oropharynx vs. NPC) | 1.683 (1.103–2.568) | 0.016 | 2.052 (1.456–2.892) | <0.001 | 2.898 (2.162–3.885) | <0.001 |
| Hypopharynx vs. NPC) | 2.188 (1.421–3.370) | <0.001 | 2.270 (1.573–3.275) | <0.001 | 3.992 (2.973–5.360) | <0.001 |
| Larynx vs. NPC) | 0.351 (0.110–1.119) | 0.077 | 1.527 (0.906–2.573) | 0.112 | 1.995 (1.294–3.078) | 0.002 |
| Sex (male vs. female) | 2.282 (1.289–4.042) | 0.005 | 2.130 (1.382–3.281) | 0.001 | 2.383 (1.646–3.452) | <0.001 |
| Smoking (yes vs. no) | 1.722 (1.169–2.538) | 0.006 | 2.636 (1.876–3.704) | <0.001 | 2.443 (1.860–3.209) | <0.001 |
| Betel quid (yes vs. no) | 1.650 (1.182–2.306) | 0.003 | 2.027 (1.553–2.644) | <0.001 | 2.209 (1.773–2.751) | <0.001 |
| Alcohol (yes vs. no) | 1.501 (1.074–2.099) | 0.017 | 2.040 (1.555–2.676) | <0.001 | 1.992 (1.594–2.488) | <0.001 |
| Chemotherapy (yes vs. no) | 1.601 (0.886–2.895) | 0.119 | 1.383 (0.890–2.148) | 0.150 | 1.144 (0.816–1.605) | 0.436 |
| Age (years)a | 0.990 (0.975–1.005) | 0.194 | 0.998 (0.987–1.010) | 0.776 | 1.024 (1.014–1.033) | <0.001 |
| Treatment daysa | 1.030 (0.995–1.066) | 0.096 | 1.026 (0.998–1.054) | 0.069 | 1.042 (1.020–1.065) | <0.001 |
| EQD2 Gy a | 1.084 (0.954–1.231) | 0.215 | 1.040 (0.946–1.144) | 0.421 | 1.062 (0.980–1.150) | 0.143 |
| PET study (yes vs. no) | 1.066 (0.657–1.731) | 0.795 | 0.760 (0.538–1.075) | 0.120 | 0.766 (0.578–1.014) | 0.063 |
| Comorbidity (yes vs. no) | 0.784 (0.555–1.108) | 0.168 | 0.997 (0.763–1.303) | 0.982 | 1.215 (0.977–1.511) | 0.081 |
| SAT index (high vs. low) | 0.585 (0.416–0.824) | 0.002 | 0.688 (0.526–0.899) | 0.006 | 0.608 (0.487–0.759) | <0.001 |
| SM index (high vs. low) | 0.800 (0.573–1.119) | 0.192 | 0.684 (0.523–0.894) | 0.005 | 0.600 (0.480–0.749) | <0.001 |
MFS, metastasis‐free survival; LRC, locoregional control; OS, overall survival; HR, hazard ratio; CI, confidence interval; NPC, nasopharyngeal carcinoma; EQD2 Gy, equivalent dose in 2‐Gy fractions; Gy, gray; PET, positron emission tomography; SAT, subcutaneous fat tissue; SM, skeletal muscle.
a
Continuous variable.